During the past decade, Kansas Institute of Medicine Cancer and Blood Center conducted 58 clinical trials. In the 10-year time frame, 58 clinical trials started and 27 clinical trials were completed, i.e. on average, 46.6% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 27 clinical trials were completed. i.e. 540% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Kansas Institute of Medicine Cancer and Blood Center" #1 sponsor was "National Cancer Institute (NCI)" with 25 trials, followed by "SWOG Cancer Research Network" with 20 trials sponsored, "Alliance for Clinical Trials in Oncology" with 13 trials sponsored, "ECOG-ACRIN Cancer Research Group" with 7 trials sponsored and "Gynecologic Oncology Group" with 7 trials sponsored. Other sponsors include 1 different institutions and companies that sponsored additional 9 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Kansas Institute of Medicine Cancer and Blood Center" #1 collaborator was "National Cancer Institute (NCI)" with 49 trials as a collaborator, "Canadian Cancer Trials Group" with 6 trials as a collaborator, "Daiichi Sankyo, Inc." with 2 trials as a collaborator, "Genentech, Inc." with 2 trials as a collaborator and "NRG Oncology" with 2 trials as a collaborator. Other collaborators include 7 different institutions and companies that were collaborators in the rest 17 trials.

According to Clinical.Site data, the most researched conditions in "Kansas Institute of Medicine Cancer and Blood Center" are "Invasive Breast Carcinoma" (5 trials), "Recurrent Breast Carcinoma" (5 trials), "Stage IIIA Breast Cancer" (5 trials), "HER2/Neu Negative" (4 trials) and "Recurrent Squamous Cell Lung Carcinoma" (4 trials). Many other conditions were trialed in "Kansas Institute of Medicine Cancer and Blood Center" in a lesser frequency.

Most popular intervention types in "Kansas Institute of Medicine Cancer and Blood Center" are "Drug" (54 trials), "Other" (48 trials), "Biological" (25 trials), "Procedure" (16 trials) and "Radiation" (6 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (29 trials), "Quality-of-Life Assessment" (16 trials), "Biospecimen Collection" (8 trials), "Computed Tomography" (8 trials) and "Nivolumab" (8 trials). Other intervention names were less common.

The vast majority of trials in "Kansas Institute of Medicine Cancer and Blood Center" are 64 trials for "All" genders, 9 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Kansas Institute of Medicine Cancer and Blood Center". undefined are not yet recruiting, 10 are recruiting, 49 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 10 completed trials in Kansas Institute of Medicine Cancer and Blood Center, 1 suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Kansas Institute of Medicine Cancer and Blood Center, 4 "Phase 1" clinical trials were conducted, 36 "Phase 2" clinical trials and 32 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 2 trials that are defined as “Not Applicable".